Protocol Ledger

NCT07217587 · Phase III · RECRUITING

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

Interventional Phase III clinical trial protocol NCT07217587 sponsored by Johnson & Johnson / Janssen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-05 Enrollment: 115 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07217587
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)115 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07217587
Protocol FieldVerified Registry Value
NCT IdentifierNCT07217587
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment115 participants (ESTIMATED)
Registered Start Date2026-01-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07217587
Hospital Research SiteLocationSite Profile
Henry Ford HospitalDetroit, MIOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI